The page you recommended will be added to the "what others are reading" feed on "My ACR".
The page you bookmarked will be added to the "my reading list" feed on "My ACR".
The U.S. Food and Drug Administration is requiring a new class warning and other safety measures for all gadolinium-based contrast agents for magnetic resonance imaging.
Read FDA announcement